Context: A heat-stable Covid-19 vaccine is being developed by the Indian Institute of Science (IISc) in Bengaluru and biotech start-up company Mynvax.
The vaccine needs no cold chain storage and has been observed to have generated strong antibody response against coronavirus variants, including Delta and Omicron, according to a study on mice.
The vaccine uses a part of the viral spike protein called the receptor-binding domain (RBD), which allows the virus to connect with the host cell to infect it.
While most vaccines require refrigeration to remain effective, the heat-tolerant Covid-19 vaccine can be stored at 37 degrees Celsius for four weeks and at 100 degrees Celsius for up to 90 minutes.
The heat tolerance of the vaccine and its ability to withstand transient thermal shocks is particularly promising to address the vaccine inequity that affects most low- and lower-middle-income countries.